These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23830054)

  • 1. Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis.
    Ji F; Zhang S; Huang N; Deng H; Li Z
    Braz J Infect Dis; 2013; 17(5):601-5. PubMed ID: 23830054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
    Aizawa N; Enomoto H; Takashima T; Sakai Y; Iwata K; Ikeda N; Tanaka H; Iwata Y; Saito M; Imanishi H; Iijima H; Nishiguchi S
    J Gastroenterol; 2014 Aug; 49(8):1253-63. PubMed ID: 24065124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of low-dose of PegIFNa-2a and ribavirin for patients with HCV-infected decompensated cirrhosis.
    Sun Y; Chang B; Teng G; Zhang W; Zhao J; Li B
    Hepatogastroenterology; 2013 Sep; 60(126):1391-8. PubMed ID: 23635509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism.
    Akahoshi T; Tomikawa M; Korenaga D; Ikejiri K; Saku M; Takenaka K
    Surg Endosc; 2010 Mar; 24(3):680-5. PubMed ID: 19690915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis.
    Hayashi PH; Mehia C; Joachim Reimers H; Solomon HS; Bacon BR
    J Clin Gastroenterol; 2006 Sep; 40(8):740-4. PubMed ID: 16940889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Akahoshi T; Maehara Y; Hayashi J;
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1728-35. PubMed ID: 24731162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
    Tamai H; Mori Y; Shingaki N; Shimizu R; Nuta J; Moribata K; Maeda Y; Muraki Y; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Takifuji K; Yamaue H; Ichinose M
    Hepatol Int; 2015 Jan; 9(1):67-75. PubMed ID: 25788381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection.
    Ikezawa K; Naito M; Yumiba T; Iwahashi K; Onishi Y; Kita H; Nishio A; Kanno T; Matsuura T; Ono A; Chiba M; Mizuno T; Aketa H; Maeda K; Michida T; Katayama K
    J Viral Hepat; 2010 Jul; 17(7):488-92. PubMed ID: 19840366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
    Foruny JR; Blázquez J; Moreno A; Bárcena R; Gil-Grande L; Quereda C; Pérez-Elías MJ; Moreno J; Sánchez J; Muriel A; Rodriguez-Sagrado MA; Moreno S
    Eur J Gastroenterol Hepatol; 2005 Nov; 17(11):1157-64. PubMed ID: 16215426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
    Hofer H; Gurguta C; Bergholz U; Steindl-Munda P; Ferenci P
    Wien Klin Wochenschr; 2006 Oct; 118(19-20):595-600. PubMed ID: 17136334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
    Motomura T; Shirabe K; Furusyo N; Yoshizumi T; Ikegami T; Soejima Y; Akahoshi T; Tomikawa M; Fukuhara T; Hayashi J; Maehara Y
    BMC Gastroenterol; 2012 Nov; 12():158. PubMed ID: 23145809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
    Aghemo A; Rumi MG; Monico S; Prati GM; D'Ambrosio R; Donato MF; Colombo M
    Antivir Ther; 2009; 14(4):577-84. PubMed ID: 19578243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
    Xie YM; Li B; Ma L; Pan L; Wei X; Peng XJ; Hao CQ; Zhang Y; Bai XF; Kang WZ; Jia ZS
    Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):112-5. PubMed ID: 22464782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus.
    Chu HC; Hsieh CB; Hsu KF; Fan HL; Hsieh TY; Chen TW
    Am J Surg; 2015 Jan; 209(1):180-6. PubMed ID: 24928331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy].
    Ma LN; He ZM; Hua W; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):594-8. PubMed ID: 24119739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
    Reiberger T; Rutter K; Ferlitsch A; Payer BA; Hofer H; Beinhardt S; Kundi M; Ferenci P; Gangl A; Trauner M; Peck-Radosavljevic M
    Clin Gastroenterol Hepatol; 2011 Jul; 9(7):602-8.e1. PubMed ID: 21397726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.
    Xu Y; Qi W; Wang X; Zhao P; Zhang Y; Zhang Q; Qin S; Wang J
    Liver Int; 2014 Nov; 34(10):1522-31. PubMed ID: 25453135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
    Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K;
    Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.